MindMaze Therapeutics Holding SA

RELIEF THERAPEUTICS Holding SA is a Swiss, commercial-stage biopharmaceutical company focused on providing innovative treatment options for rare debilitating conditions with limited or no existing treatments. The company has historically maintained a diverse portfolio of marketed products and developmental product candidates, many of which utilize its proprietary drug delivery platform technologies. Following a comprehensive review, RELIEF THERAPEUTICS is now strategically refocusing its business on products addressing rare dermatological conditions where there is significant unmet need. For other commercial and development-stage products in its portfolio, the company is actively seeking partners through out-licensing, divestitures, or other collaboration transactions. As part of this strategy, on March 21, 2024, the company entered into an exclusive license and supply agreement with Eton Pharmaceuticals, Inc. for the commercialization of the GOLIKE family of products in the United States. The company is also concentrating its efforts on advancing RLF-TD011, a self-administered, sprayable acid oxidizing solution of hypochlorous acid, which is currently being studied for the treatment of wounds in epidermolysis bullosa. In 2023, 2022, and 2021, capital expenditures amounted to CHF 937,000, CHF 567,000, and CHF 71,000, respectively, primarily for laboratory equipment, software, and office furniture.